An open-label, phase I, repeat dose-escalation study of ABR-217620 [naptumomab estafenatox] in patients with advanced non-small cell lung cancer, renal clear cell carcinoma or pancreatic cancer
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2014
At a glance
- Drugs Naptumomab estafenatox (Primary)
- Indications Non-small cell lung cancer; Pancreatic cancer; Renal cancer; Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Active Biotech
- 05 Mar 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Sep 2005 New trial record.